Deepak Shrivastava
Talking Points on Deprescribing in Hospice Care
Deepak Shrivastava
Talking Points on Deprescribing in Hospice Care
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Deprescribing practice in hospice medicine has expanded exponentially in recent years. This book systematically addresses the groups of extremely useful medications to manage chronic disease conditions and prevent complications.
Andere Kunden interessierten sich auch für
- Ellen Long Stilwell RN CHPNHOSPICE16,99 €
- Neonatal Palliative Care for Nurses56,99 €
- Ken PettitThey Call Me "Doctor Death"19,99 €
- Alan MolkSaving Lives, Saving Dignity15,99 €
- Ken PettitThey Call Me "Doctor Death"25,99 €
- Alan MolkSaving Lives, Saving Dignity22,99 €
- Hospice Palliative Home Care and Bereavement Support48,99 €
-
-
-
Deprescribing practice in hospice medicine has expanded exponentially in recent years. This book systematically addresses the groups of extremely useful medications to manage chronic disease conditions and prevent complications.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Taylor & Francis Ltd
- Seitenzahl: 169
- Erscheinungstermin: 23. April 2024
- Englisch
- Abmessung: 198mm x 129mm
- Gewicht: 510g
- ISBN-13: 9781032491080
- ISBN-10: 1032491086
- Artikelnr.: 70149917
- Verlag: Taylor & Francis Ltd
- Seitenzahl: 169
- Erscheinungstermin: 23. April 2024
- Englisch
- Abmessung: 198mm x 129mm
- Gewicht: 510g
- ISBN-13: 9781032491080
- ISBN-10: 1032491086
- Artikelnr.: 70149917
Deepak Shrivastava, MD is a board-certified Hospice Medical Director. In addition, he holds board certifications in Internal Medicine, Sleep Medicine, Pulmonary and Critical Care Medicine and Post-Acute and Long-Term Care. He is an academic and clinical faculty at the Sleep, Critical Care and Pulmonary division. He is a Clinical Professor at the University of California. He is an adjunct Professor of Pharmacy at the University of Pacific, School of Pharmacy. He is the recipient of many academic and service awards including the Medical Director of the Year award (2015) at the American Medical Directors Association. Dr. Shrivastava received his training at the State University of New York, University of California, Davis and Stanford. He is an active researcher with a keen interest in medical education. He is directly involved in health care quality and performance improvement. In addition to his active practice of Pulmonary, Critical Care and Sleep Medicine in an ACGME-accredited teaching program, he has been involved in Medicare Hospice Benefit Program since 1989. He is a member of the National Partnership for Healthcare and Hospice Innovation (NPHI). His areas of interest are clinical nursing and hospice physician education, and performance improvement in hospice care.
1. Introduction
2. Physiologic changes of terminal illness
3. Fundamentals of deprescribing
4. Deprescribing Statins
5. Deprescribing Benzodiazepines
6. Deprescribing Antipsychotics
7. Deprescribing SSRI and SNRIs
8. Deprescribing Tricyclic Antidepressants
9. Deprescribing Anticholinergic drugs for parkinsonism
10. Deprescribing Anticholinergic drugs for urinary incontinence
11. Deprescribing muscle relaxants
12. Deprescribing long-term Opioids
13. Deprescribing Proton Pump Inhibitors
14. Deprescribing Allopurinol
15. Deprescribing Antihyperglycemics Oral
16. Deprescribing Antihyperglycemics Injectable
17. Deprescribing anti-hypertensives
18. Deprescribing Anticoagulants
19. Deprescribing Cholinesterase inhibitors
20. Deprescribing Glaucoma eye drops
21. Deprescribing Vitamin D and Calcium
22. Deprescribing NSAIDs
23. Deprescribing gabapentin and pregabalin
24. Deprescribing long-acting Beta agonist
25. Deprescribing Vitamins
26. Deprescribing medications in children
27. Deprescribing in Transgender and LGBTQ
28. Cultural competency in deprescribing
29. Chaplain and medical social worker
30. When to restart discontinued medications.
31. Medicolegal aspects of deprescribing
2. Physiologic changes of terminal illness
3. Fundamentals of deprescribing
4. Deprescribing Statins
5. Deprescribing Benzodiazepines
6. Deprescribing Antipsychotics
7. Deprescribing SSRI and SNRIs
8. Deprescribing Tricyclic Antidepressants
9. Deprescribing Anticholinergic drugs for parkinsonism
10. Deprescribing Anticholinergic drugs for urinary incontinence
11. Deprescribing muscle relaxants
12. Deprescribing long-term Opioids
13. Deprescribing Proton Pump Inhibitors
14. Deprescribing Allopurinol
15. Deprescribing Antihyperglycemics Oral
16. Deprescribing Antihyperglycemics Injectable
17. Deprescribing anti-hypertensives
18. Deprescribing Anticoagulants
19. Deprescribing Cholinesterase inhibitors
20. Deprescribing Glaucoma eye drops
21. Deprescribing Vitamin D and Calcium
22. Deprescribing NSAIDs
23. Deprescribing gabapentin and pregabalin
24. Deprescribing long-acting Beta agonist
25. Deprescribing Vitamins
26. Deprescribing medications in children
27. Deprescribing in Transgender and LGBTQ
28. Cultural competency in deprescribing
29. Chaplain and medical social worker
30. When to restart discontinued medications.
31. Medicolegal aspects of deprescribing
1. Introduction
2. Physiologic changes of terminal illness
3. Fundamentals of deprescribing
4. Deprescribing Statins
5. Deprescribing Benzodiazepines
6. Deprescribing Antipsychotics
7. Deprescribing SSRI and SNRIs
8. Deprescribing Tricyclic Antidepressants
9. Deprescribing Anticholinergic drugs for parkinsonism
10. Deprescribing Anticholinergic drugs for urinary incontinence
11. Deprescribing muscle relaxants
12. Deprescribing long-term Opioids
13. Deprescribing Proton Pump Inhibitors
14. Deprescribing Allopurinol
15. Deprescribing Antihyperglycemics Oral
16. Deprescribing Antihyperglycemics Injectable
17. Deprescribing anti-hypertensives
18. Deprescribing Anticoagulants
19. Deprescribing Cholinesterase inhibitors
20. Deprescribing Glaucoma eye drops
21. Deprescribing Vitamin D and Calcium
22. Deprescribing NSAIDs
23. Deprescribing gabapentin and pregabalin
24. Deprescribing long-acting Beta agonist
25. Deprescribing Vitamins
26. Deprescribing medications in children
27. Deprescribing in Transgender and LGBTQ
28. Cultural competency in deprescribing
29. Chaplain and medical social worker
30. When to restart discontinued medications.
31. Medicolegal aspects of deprescribing
2. Physiologic changes of terminal illness
3. Fundamentals of deprescribing
4. Deprescribing Statins
5. Deprescribing Benzodiazepines
6. Deprescribing Antipsychotics
7. Deprescribing SSRI and SNRIs
8. Deprescribing Tricyclic Antidepressants
9. Deprescribing Anticholinergic drugs for parkinsonism
10. Deprescribing Anticholinergic drugs for urinary incontinence
11. Deprescribing muscle relaxants
12. Deprescribing long-term Opioids
13. Deprescribing Proton Pump Inhibitors
14. Deprescribing Allopurinol
15. Deprescribing Antihyperglycemics Oral
16. Deprescribing Antihyperglycemics Injectable
17. Deprescribing anti-hypertensives
18. Deprescribing Anticoagulants
19. Deprescribing Cholinesterase inhibitors
20. Deprescribing Glaucoma eye drops
21. Deprescribing Vitamin D and Calcium
22. Deprescribing NSAIDs
23. Deprescribing gabapentin and pregabalin
24. Deprescribing long-acting Beta agonist
25. Deprescribing Vitamins
26. Deprescribing medications in children
27. Deprescribing in Transgender and LGBTQ
28. Cultural competency in deprescribing
29. Chaplain and medical social worker
30. When to restart discontinued medications.
31. Medicolegal aspects of deprescribing